PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Account Payables

Last Annual Value

822.00K

3-Year CAGR

-15%

5-Year CAGR

3%

10-Year CAGR

19%

PepGen Inc.

PepGen Inc. Competitors Analysis of Account Payables

PEPG · NASDAQ
CompanyAccount Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
822.00K
-6.5%-24.0%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
1.69M
-23.5%-18.7%3.9%
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
2.09M
-17.1%13.4%N/A
4.43M
36.5%-14.1%N/A
1.52M
-23.6%N/AN/A
1.88M
20.5%25.6%N/A
858.00K
-16.0%-28.2%N/A
6.27M
31.3%42.8%N/A
779.00K
-13.7%-32.5%N/A
0.00
N/AN/AN/A
2.21M
-11.3%4.4%-4.3%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642